Senseonics reported a preliminary unaudited revenue of approximately $14.2 million for Q4 2025, marking a 71% year-over-year increase.
They introduced a revenue guidance of $58-$62 million for 2026, showing significant growth expectations.
The company achieved 103% new patient growth in the U.S. in Q4 2025 compared to the same period in 2024.
Record Revenue
Q4 2025 revenue of $14.2 million and $35.2 million for 2025 are the largest in company history.
Patient Growth
Achieved 103% new patient growth, driven by successful DTC marketing efforts.
Strategic Partnerships
Secured agreements with Ascensia for Eversense commercialization and distribution in the U.S.
Upcoming Developments
Anticipated launch of twiist system with full Eversense compatibility and completion of the Gemini trial in 2026.
- Senseonics closed 2025 with record revenues, fuelled by successful DTC initiatives.
- The transition of Eversense commercial rights is expected to boost revenue and gross margins in 2026.
- Anticipated CE mark in Europe and partnerships indicate a positive outlook for the company's future growth.
Senseonics looks forward to a promising 2026 with key developments and growth opportunities in the pipeline. The transition of Eversense commercial rights and new product launches are expected to drive shareholder value.